Kelvin Capital was founded in 2009 and has since raised a total of over £50million into 28 portfolio companies. We invest venture capital in revenue generating growth companies which have the potential to deliver significant return to their investors. They also invest in companies that require capital to grow their business. For the right company with the right team, Kelvin Capital provides the investment and the support needed to deliver the true potential of their business. The Kelvin Capital team has a combined 30 years experience of working with new businesses and understands both the challenges and opportunities, which will be encountered during the high growth phase. The team has built up extensive networks, which will be made available to assist and support the portfolio businesses. Kelvin Capital will actively promote the portfolio businesses through its website and social media activities raising their awareness and profile. The entire Kelvin Capital team is focused on the success of their portfolio of businesses.

Kelvin Capital

Scottish Enterprise is Scotland's main economic development agency and a non-departmental public body of the Scottish Government. The firm wants to stimulate Scotland’s economic ambition – creating an innovative, high-wage and highly productive economy with a competitive, international market presence and a focus on high value opportunities. Scottish Enterprise partners with the public and private sectors to identify and exploit the best opportunities to deliver a significant, lasting effect on the Scottish economy.

Scottish Enterprise

They help companies to identify appropriate sources of finance, engage with funders and secure the investment they need to grow their business. They work closely with their portfolio companies to strengthen their management teams, make connections and accelerate growth. Their work also involves aiming to increase the supply of finance for businesses in Scotland. they want to help Scottish SMEs with growth and export potential to get this finance. Apart from supporting Scottish businesses, they also work with UK and international investors. This includes working with business angels, angel syndicates, venture capital groups and corporate investors. They operate across Scotland in partnership with Highlands and Islands Enterprise. Because their work supports and stimulates the SME funding market in Scotland, what they do supports the delivery of the Scottish Enterprise business plan.

Scottish Investment Bank

Biotangents

Biotangents was founded upon their Leapfrog Assembly™ platform technology for building complex genetic constructs from multiple DNA parts. This was developed through a SMART: Scotland award from Scottish Enterprise and was exe0mplified through the generation of their terpenoid biosynthesis strains. During that successful first year they also developed their DNA randomisation technology, Short Sequence Randomisation™. In 2016, having formulated a concept for a modular cell-free nucleic acid detection technology, Moduleic Sensing™, and with support from SynbiCITE, they commenced development of their first diagnostic test, a highly specific and sensitive solution for pen-side diagnosis of infectious diseases in livestock.

Biotangents is a UK-based biotechnology company specializing in developing diagnostic tests for infectious diseases in livestock. Founded by Dr. Andy Hall-Ponselè and Lina Gasiūnaitė, the company aims to enhance the sustainability and efficiency of traditional industries through genetic technologies. Biotangents leverages advanced molecular techniques, such as machine learning and proprietary algorithms, to design and produce high-performance diagnostic tests that provide quick and accurate results, enabling early disease detection.

Driving livestock productivity using next-generation biotechnology

Livestock Biotech

Biotangents secures £2.3m from Eos to revolutionise dairy farming

Biotangents is a UK-based biotechnology company specializing in developing diagnostic tests for infectious diseases in livestock. Founded by Dr. Andy Hall-Ponselè and Lina Gasiūnaitė, the company aims to enhance the sustainability and efficiency of traditional industries through genetic technologies. Biotangents leverages advanced molecular techniques, such as machine learning and proprietary algorithms, to design and produce high-performance diagnostic tests that provide quick and accurate results, enabling early disease detection.In 2016, the company developed modular cell-free nucleic acid detection technology, Moduleic Sensing™, which allows rapid adaptation to various diagnostic needs across livestock industries. Its next-generation molecular diagnostics assay, AmpliSpec™ LAB Mastitis, has been designed to rapidly identify bovine mastitis pathogens, requiring only 70 minutes to deliver results.&nbsp;&nbsp;&nbsp;

<div>
 
 Aviabiotic (formerly Chicken Probiotic) is a biotechnology company innovating in poultry health. The company specializes in creating probiotics engineered for enhanced thermostability, elimination of antibiotic resistance, and dependency on corn sugar, making them environmentally friendly. These probiotics are designed specifically for integrated poultry operations, addressing both health and efficiency in poultry production.
 
 
 
 
 Funding and financials
 
 
 
 
 Aviabiotic's latest funding was a grant received in 2020, which has facilitated the development and commercialization of its specialized probiotics.&nbsp;
 
 
 
</div>

Aviabiotic

<div>
 
 ZeaVaxx is an animal healthcare company using advanced biotechnology to improve vaccine effectiveness for animals. Its plant-derived nanoparticle adjuvant platform claims to offer advantages over aluminum-based ones that are falling short in current animal vaccine formulations due to low efficacy and compatibility issues. This platform is designed to enhance the immunogenicity of vaccines to ensure that the vaccines can provoke a stronger and more effective immune response in animals.
 
 
 
 
 ZeaVaxx flagship product, Zea-11, is a proprietary glucan-based nanoparticle derived from plants. Zea-11 claims to offer simplified extraction and chemical finalization, making it the first economically viable nanoparticle adjuvant for animal vaccines.&nbsp;
 
 
 
 
 Funding and financials
 
 
 
 
 In June 2018, the company secured USD 50,000 in pre-seed funding from the Purdue Ag-celerator.
 
 
 
</div>

ZeaVaxx

<div>
 
 Malcisbo, a spin-off from the Swiss Federal Institute of Technology Zurich (ETH Zurich), is a Swiss biotechnology company developing novel vaccines for animal and human health. The company focuses on glycoengineering technologies to create efficient glycoconjugate vaccines to address bacterial diseases that impact animal health, human food safety, and zoonotic diseases.
 
 
 
 
 Its primary product offerings target Campylobacter infections in humans (to reduce food poisoning from chicken meat) and Actinobacillus pleuropneumoniae (to reduce economic losses in the swine industry due to mortality, growth retardation, and the need for antibiotics).
 
 
 
 
 Funding and financials
 
 
 
 
 As of May 2024, the company had been awarded 10 grants totaling CHF 3.5 million (~USD 3.8 million).
 
 
 
</div>

Malcisbo

<div>
 
 eggXYt is an Israeli biotech company that specializes in ultrasound technology for eggs. The company has developed a non-invasive, pre-incubation sex detection technology for chicken embryos, named seXYt, which allows poultry farmers to separate male and female layer chicks before incubation. This process claims to prevent unnecessary incubation of over 8 billion male layer chicks annually, which are otherwise disposed of after birth due to their unsuitability for the industry. These eggs are then repurposed and used outside the food industry, leading to lower costs and reduced resource waste in hatcheries.
 
 
 
 
 Key customers and partnerships
 
 
 
 
 In November 2020, the company signed an R&amp;D licensing agreement with Tropic Biosciences to develop Avian influenza resistance in chickens through gene editing.
 
 
 
 
 Funding and financials
 
 
 
 
 eggXYt has received over USD 2.5 million in funding from the European Union through the Horizon 2020 SME Program for its sex detection technology and to expand its research into new areas such as disease resistance in poultry.
 
 
 
</div>

eggXYt

<div>
 
 BioRefic is a Latvian biotech company that develops biorefinery technology to produce advanced prebiotic ingredients and microbial Omega-3 fatty acids. It primarily serves the animal feed and aquaculture sectors by providing sustainable alternatives to traditional feed ingredients. Biorefic&rsquo;s products, which include xylooligosaccharide prebiotic (a gut microbiome enhancing ingredient to improve health and immunity and boost performance), are designed to enhance animal health and efficiency, thus reducing the overall environmental impact of agriculture.
 
 
 
 
 Funding and financials
 
 
 
 
 BioRefic has raised a total of EUR 250,000 in funding over two rounds, with its most recent funding coming from a non-equity assistance round supported by RootCamp. 
 
 
 
</div>

BioRefic

Companies that offer solutions that edit (gene editing) or modify (gene modification) an animal's genome in a precise and targeted manner using methods such as TALEN's, CRISPR/Cas9, recombinant retroviruses, and sperm-mediated DNA transfer. The techniques change the existing genome to improve/express desired traits in livestock. The segment also covers companies that use an AI-based platform or otherwise to offer diagnostic testing services of the animal's genome that help livestock farmers identify genetic changes or diseases present in herds.

Companies that offer next-generation vaccines based on developments in DNA technology (e.g., mRNA vaccines) and biotechnology. The segment also includes medicines developed for the prevention and treatment of livestock diseases.

Companies that use a range of genetic techniques that can alter the DNA of animals more precisely than traditional breeding techniques. Techniques such as gender selection via sexed semen, genomic selection, or even gene editing methods like CRISPR are used to breed animals precisely with superior genetic traits.

Companies that produce natural ingredients or biological additives that can be added to animal feed for purposes such as improving nutrient uptake and the gut microbiome.

Biotech solutions to grow livestock that are of better traits and sustainable

Uses AI/machine learning to facilitate their platform/biotech processes like gene editing

Offers customization of genes and traits as required by farmers

<div>
 UK-based livestock diagnostics company, Biotangents, has received GBP 2.3 million (~USD 2.9 million) of funds from a financing led by Eos and British Business Investments via their Regional Angels Programme along with contributions from Kelvin Capital and Scottish Enterprise.
 These funds will be utilized to initiate on-farm trials throughout the UK and internationally by the end of 2025.
 Biotangents' technology offers on-farm molecular diagnostic results in under two hours for dairy cow diseases like bovine mastitis. This particular disease costs the worldwide dairy farming sector approximately GBP 20 billion (~USD 25 billion) per year and, on an individual level, can cost upto GBP 25,000 (~USD 32,000) per UK dairy farm.
 
</div>

Biotangents

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless